|Bid||156.78 x 1000|
|Ask||156.91 x 900|
|Day's range||155.31 - 159.67|
|52-week range||117.08 - 464.00|
|Beta (5Y monthly)||-0.70|
|PE ratio (TTM)||5.00|
|Earnings date||09 Nov 2021|
|Forward dividend & yield||2.11 (1.33%)|
|Ex-dividend date||02 Jun 2022|
|1y target est||320.42|
Pfizer (NYSE: PFE) is already the leader in the coronavirus vaccine space. Rival Moderna (NASDAQ: MRNA) has a significant position in the market. Latecomer Novavax (NASDAQ: NVAX) could also take market share in the months to come.
The team behind Britain’s most-used Covid booster vaccine is being sued by a German pharmaceutical firm which has accused it of stealing the technology behind the jab.
BERLIN (Reuters) -CureVac has filed a patent lawsuit in Germany against BioNTech over its use of mRNA technology, marking one of the first known cases of a company going to court amid the fierce competition to develop a vaccine against the coronavirus. The German-based biotech company is seeking "fair compensation" from BioNTech and two subsidiaries for infringement of its intellectual property rights, it said on Tuesday. When asked in a media call, Chief Executive Franz-Werner Haas did not rule out further legal action against BioNTech partner Pfizer or mRNA vaccine maker Moderna.